Overview

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Erlotinib Hydrochloride